{"disease":{"id":"infections-papillomavirus","name":"infections papillomavirus"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00534638","title":"Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":34412,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00122681","title":"Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":18729,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00779766","title":"Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":6081,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00294047","title":"Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5752,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01101542","title":"Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females","phase":"","overall_status":"COMPLETED","enrollment_count":3091,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00937950","title":"Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2022,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01381575","title":"Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1447,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00369824","title":"Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1330,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01277042","title":"Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1212,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00423046","title":"Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1106,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01462357","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1079,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00316693","title":"Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1046,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00541970","title":"Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":961,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01031069","title":"Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":873,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00578227","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":814,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00552279","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":805,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00250276","title":"Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":798,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00426361","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":751,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00996125","title":"Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00652938","title":"Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":744,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00196937","title":"Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":667,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00877877","title":"Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":632,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00478621","title":"Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":540,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT00947115","title":"Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":525,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00231413","title":"Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":383,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00359619","title":"Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":383,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00344032","title":"Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":354,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00799825","title":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":346,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00345878","title":"Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":271,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00309166","title":"Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00485732","title":"A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01249365","title":"The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01418937","title":"Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00637195","title":"Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":152,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00586339","title":"Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01627561","title":"Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01190189","title":"Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00546078","title":"Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00492544","title":"Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04587050","title":"Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV","phase":"","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT06919627","title":"Negative HPV Test Results on Infinity/GeneXpert® With the Presence of a Late Amplification Signal: What Does This Mean ? (PaPCR)","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT01190176","title":"Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00549900","title":"A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05797246","title":"Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06854354","title":"Intervention for Human Papillomavirus Vaccine Acceptance in Mexican Mothers","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Hospital Univeristario Benemerita Universidad Autonoma de Puebla","has_results":false},{"nct_id":"NCT01290393","title":"Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada","phase":"","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"GlaxoSmithKline","has_results":false}],"total":46},"guidelines":[],"source":"Drug Landscape verified database"}